Evidence map›Paper›PMID 42162121›Full record

ArticleScientific reports2026

Cost-effectiveness of community interventions to promote awareness, testing and treatment of hepatitis B and C in migrant populations in Catalonia.

Elisa Martró, Raquel Domínguez-Hernández, Venus Forero, Jordi Gómez I Prat, Anna Not, Sandra Manzanares-Laya, Marcos Montoro, Manuel Gómez-Barrera, Maria Buti, Jordi Casabona and 2 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Elisa Martró *Microbiology Department, Laboratori Clínic Metropolitana Nord (LCMN), Germans Trias i Pujol Research Institute and Hospital (IGTP), Carretera de Canyet, s/n, 08916, Badalona, Barcelona, Spain. emartro@igtp.cat.
Raquel Domínguez-Hernández *Pharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain.
Venus ForeroSubdirectorate General of Addictions, HIV, STI and Viral Hepatitis, Public Health Agency of Catalonia (ASPCAT), Barcelona, Spain.
Jordi Gómez I PratCommunity & Public Health Team (ESPIC), Drassanes-Vall d'Hebron Centre for International Health and Infectious Diseases, Barcelona, Spain.
Anna NotMicrobiology Department, Laboratori Clínic Metropolitana Nord (LCMN), Germans Trias i Pujol Research Institute and Hospital (IGTP), Carretera de Canyet, s/n, 08916, Badalona, Barcelona, Spain.
Sandra Manzanares-LayaSubdirectorate General of Addictions, HIV, STI and Viral Hepatitis, Public Health Agency of Catalonia (ASPCAT), Barcelona, Spain.
Marcos MontoroCentre d'Estudis Epidemiològics sobre les ITS i la Sida de Catalunya (CEEISCAT), ASPCAT, Badalona, Barcelona, Spain.
Manuel Gómez-BarreraPharmacoeconomics & Outcomes Research Iberia (PORIB), Madrid, Spain.
Maria ButiLiver Unit, Hospital Universitari Vall Hebrón, Barcelona, Spain.
Jordi CasabonaConsorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.
Xavier MajóSubdirectorate General of Addictions, HIV, STI and Viral Hepatitis, Public Health Agency of Catalonia (ASPCAT), Barcelona, Spain.
Joan ColomSubdirectorate General of Addictions, HIV, STI and Viral Hepatitis, Public Health Agency of Catalonia (ASPCAT), Barcelona, Spain.

Funding

Instituto de Salud Carlos III (Co-funded by European Regional Development Fund "A way to make Europe") PI19/0568Instituto de Salud Carlos III, Fondo Social Europeo FI20/00211
6 · The paper itself

Abstract

Interventions aimed at the diagnosis of viral hepatitis in migrants from countries with high prevalence rates are essential to achieve the elimination of viral hepatitis. The objective was to perform a cost-effectiveness analysis of a community screening strategy for hepatitis B and C virus (HBV and HCV) infections versus no intervention in migrant populations in Catalonia. HBV and HCV decision trees for the community strategy (from community screening to simplified access to care and treatment) and Markov models to simulate hepatitis B and C disease progression were developed. Sensitivity analyses were performed with the parameters with the highest uncertainty. Among the 2291 people screened, 74 and 21 cases of HBV and HCV infection were diagnosed, which avoided 79% and 62% of liver complications related to HBV and HCV, respectively. Community HCV screening showed an incremental cost of €13,999/patient versus no intervention and 2.98 quality-adjusted life years (QALYs) per patient, resulting in an incremental cost‒utility ratio of €4692/QALY gained. The HBV strategy was dominant. The distribution of HCV patients across different fibrosis stages had a greater impact on sensitivity analyses. Implementing a community screening strategy, which also increased awareness of HBV and HCV infections and treatment in migrant populations, is cost-effective.

Indexed as

Cost-Benefit AnalysisHepatitis BHepatitis CMass ScreeningTransients and MigrantsAdultCost-Effectiveness AnalysisFemaleHumansMaleMiddle AgedQuality-Adjusted Life YearsSpainCommunityCost-effectivenessHBVHCVMigrantsScreeningTreatment

Identifiers

PMID42162121
PMCPMC13389037

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.